OZEMPIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OZEMPIC (OZEMPIC).
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the action of endogenous GLP-1, which increases insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. The primary mechanism is activation of GLP-1 receptors on pancreatic beta cells, leading to glucose-dependent insulin release.
| Metabolism | Semaglutide is metabolized via proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain. No specific CYP450 enzymes are involved. |
| Excretion | Primarily renal (80%) and biliary/fecal (20%). Unchanged parent drug accounts for ~5-10%; majority is degraded into small peptides/amino acids. |
| Half-life | Terminal elimination half-life approximately 1 week (5–7 days) in subcutaneous dosing, allowing once-weekly administration. Steady state reached after 4–5 weeks. |
| Protein binding | >99% bound to albumin. |
| Volume of Distribution | Approximately 0.12 L/kg (mean ~8.3 L), indicating limited extravascular distribution and confinement primarily to plasma and interstitial fluid. |
| Bioavailability | Subcutaneous: 89% (95% CI: 80–97%). Not orally bioavailable due to peptide degradation. |
| Onset of Action | Subcutaneous: Glycemic effects begin within 2–3 weeks; maximal glucose-lowering effect by 8 weeks. Dose-dependent delay in gastric emptying occurs within first dose. |
| Duration of Action | Pharmacodynamic effects last approximately 1 week (7 days) after a single subcutaneous dose, supporting once-weekly dosing. Gastric emptying effects persist for 12–16 hours per dose. |
1 mg subcutaneously once weekly, starting at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly for at least 4 weeks before escalating to 1 mg.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR 30-89 mL/min. Avoid use if GFR < 30 mL/min due to limited data and potential for gastrointestinal adverse effects. |
| Liver impairment | No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution. |
| Pediatric use | Not approved for pediatric patients; no established dosing guidelines. |
| Geriatric use | No specific dose adjustment needed based on age; monitor renal function due to age-related decline and consider cautious titration due to increased risk of gastrointestinal effects and dehydration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OZEMPIC (OZEMPIC).
| Breastfeeding | No human data. Excreted in rat milk with M/P ratio unknown. Risk to infant cannot be excluded; consider discontinuing breastfeeding or drug. |
| Teratogenic Risk | No adequate human studies. Animal studies show fetal growth retardation, skeletal anomalies, and increased pregnancy loss at exposures similar to human exposure. Risk cannot be excluded in first trimester. Second and third trimester: potential for fetal pancreatic beta-cell hyperplasia and altered glucose homeostasis. |
| Fetal Monitoring |
■ FDA Black Box Warning
No FDA black box warning exists for Ozempic.
| Serious Effects |
["Personal or family history of medullary thyroid carcinoma (MTC)","Multiple endocrine neoplasia syndrome type 2 (MEN-2)","Known hypersensitivity to semaglutide or any product components","Not for use in type 1 diabetes mellitus or diabetic ketoacidosis"]
| Precautions | ["Risk of thyroid C-cell tumors: Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2).","Acute pancreatitis: Discontinue if suspected.","Diabetic retinopathy complications: Increased risk, especially in patients with a history of retinopathy.","Hypoglycemia: Increased risk when used with insulin or insulin secretagogues.","Renal impairment: Acute kidney injury reported; monitor renal function.","Gastrointestinal effects: Nausea, vomiting, diarrhea; may cause volume depletion.","Hypersensitivity: Serious allergic reactions reported."] |
Loading safety data…
| Monitor blood glucose, HbA1c, and weight. Ultrasound for fetal growth and amniotic fluid volume. Monitor for maternal gastrointestinal adverse effects (nausea, vomiting) that may affect hydration and electrolyte balance. |
| Fertility Effects | In animal studies, no adverse effects on fertility. No human data; theoretical risk based on effect on body weight and metabolism. |